Windows 8: A ‘Christmas gift for someone you hate’

Microsoft (MSFT) is no stranger to criticism these days, and the company’s new Windows 8 platform is once again the target of a scathing review from a high-profile user. Well-known Internet entrepreneur and MIT professor Philip Greenspun handed Windows 8 one of its most damning reviews yet earlier this week, calling the new operating system a “Christmas gift for someone you hate.” Greenspun panned almost every aspect of Microsoft’s new software, noting that Microsoft had four years to study Android and more than five to examine iOS, but still couldn’t build a usable tablet experience.

“The only device that I can remember being as confused by is the BlackBerry PlayBook,” Greenspun wrote on his blog after using Windows 8 on a Dell (DELL) XPS One All-in-One desktop PC. The acclaimed computer scientist noted that Microsoft omitted all of the best features from the most popular touch-focused platforms and instead created a user interface he describes as a “dog’s breakfast.”

“Suppose that you are an expert user of Windows NT/XP/Vista/7, an expert user of an iPad, and an expert user of an Android phone… you will have no idea how to use Windows 8,” Greenspun wrote.

He continued, “Some functions, such as ‘start an application’ or ‘restart the computer’ are available only from the tablet interface. Conversely, when one is comfortably ensconced in a touch/tablet application, an additional click will fire up a Web browser, thereby causing the tablet to disappear in favor of the desktop. Many of the ‘apps’ that show up on the ‘all apps’ menu at the bottom of the screen (accessible only if you swipe down from the top of the screen) dump you right into the desktop on the first click.”

The only praise Greenspun offered was that “some of the supplied apps are wonderful,” pointing to Microsoft’s Bing Finance application as an example.

Get more from BGR.com: Follow us on Twitter, Facebook

Wireless News Headlines – Yahoo! News

Read More..

Breast Cancer Vaccine a Reality for Women With HER-2 Negative Cancers

COMMENTARY | NeuVax, a breast cancer vaccine, is entering phase III trials. The drug’s manufacturer, Galena Biopharma, announced on Dec. 5, that it signed a distribution deal with TEVA Pharmaceuticals. TEVA will handle the global commercialization and distribution of the drug once it is out of trials. It is about time this is moving forward. We need to make progress toward ending this disease.

What is NeuVax?

A vaccine called NeuVax is close to being a reality for breast cancer patients. NeuVax is a vaccine, the first of its kind, to prevent breast cancer from recurring. A recurrence is when breast cancer returns to the same breast. If breast cancer appears in the other breast, it is not a recurrence but a new cancer.

Most women have a 15-20 percent chance of breast cancer recurring, even after a mastectomy. The implications of the vaccine are huge. It reduces the chance of breast cancer recurrence in women with node-positive, HER-2 negative breast cancers. About 75 percent of all breast cancer is HER-2 negative. The vaccine is given after the standard course of treatment is completed. It is not a replacement for radiation or chemotherapy. I would gladly try a vaccine over the currently available long-term recurrence preventions — all are hormone based and carry awful side effects.

Phase III trials

Unfortunately for me, there are no trials available in Arkansas. Even if there were, I am not eligible because my cancer is HER-2 positive, and I am thankfully, node-negative. This means that the cancer is not in my lymph system. Phase III trials are when the drug is actually tested in random settings on humans. This drug seems to be very promising. Right now, phase III trials are open in the United States and Canada. Israel will have at least four phase III trials opening soon. You can see if there are trials near you at the NeuVax website.

This vaccine has the potential to replace hormone therapies like tamoxifen and aromatase inhibitors. Both types of drugs have serious side effects. A vaccine, taken over the course of three years, reduces the time a patient needs to take medications and it helps to prevent recurrence. Hopefully the phase III trials go well and we get this vaccine available to breast cancer patients soon.

Lynda Altman was diagnosed with breast cancer in November 2011. She writes a series for Yahoo! Shine called “My Battle With Breast Cancer.”

Medications/Drugs News Headlines – Yahoo! News

Read More..

“Community”: Jason Alexander filming “Crazy” guest spot

LOS ANGELES (TheWrap.com) – “Community” might be losing a Chevy Chase, but it’s gaining a Jason Alexander.

Former “Seinfeld” star Alexander, who played neurotic bumbler George Costanza on the series, will guest-star on the beleaguered NBC comedy, and while the actor is tight-lipped on the details, he promises that the episode will be a doozy.

“Filming a crazy episode of ‘Community’ this week,” the actor tweeted early Tuesday. “Can’t say much about it but it’s a fun one.”

It is not known what role Alexander, who guest-starred on “Two and a Half Men” earlier this year, will play on the series, or if he will appear on more than one episode. A spokeswoman for the NBC series has not yet responded to TheWrap’s request for comment.

Last month, news broke that Chevy Chase – who plays Pierce Hawthorne on the series – is leaving “Community,” following an ugly standoff with the show’s creator and former showrunner, Dan Harmon, and an incident when he reportedly tossed out the N-word, after complaining about his character’s racism. Chase will appear in most of the episodes of the upcoming fourth season.

“Community” returns to the air February 7.

TV News Headlines – Yahoo! News

Read More..

Sri Lanka see backlash from Aussie ‘wounded soldiers’

(Reuters) – Sri Lanka captain Mahela Jayawardene has warned his team to be wary of a backlash from Australia in their three-test series after the hosts were stung by their series defeat to South Africa earlier this week.

Australia’s hopes of snatching the Proteas’ top test ranking ended in a crushing 309-run defeat in the third and final test in Perth on Monday, but Jayawardene took little comfort from the home side’s disappointment.

“I see them as wounded soldiers – they could come back stronger against us,” Jayawardene told reporters in Canberra on Wednesday, on the eve of a three-day tour match against a Chairman’s XI side.

“So we just need to make sure we are ready for that and start well.

“We can’t be complacent – we need to make sure we know from ball one we give them a good go at it.”

Sri Lanka have their own problems coming into the first test at Hobart next week, losing their last test at home to New Zealand by 167 runs to level a two-match series 1-1, with key batsmen out of form.

Kumar Sangakkara scored five, nought and 16 in his three innings against New Zealand, but Jayawardene backed the veteran to bounce back in Sri Lanka’s bid to win their first test Down Under.

“I am happy that he went through a lean phase because he’ll be really hungry for runs – that’s Kumar for you,” Jayawardene said of the 35-year-old stalwart.

Jayawardene also said he would weigh up his future as captain after the series, which includes tests in Melbourne and Sydney, after taking on the role for a second time in the wake of Tillakaratne Dilshan’s sudden resignation in January.

“After this, we get a well-deserved four weeks off, after about three years, so it gives me a bit of time to think (about) what I need to do,” said Jayawardene, who captained the team for more than three years in his first stint from 2006.

“We need to groom another leader as well. It’s very important to have that changeover done smoothly while the senior players are still in the side.”

Australia / Antarctica News Headlines – Yahoo! News

Read More..

“The Message” deemed greatest hip hop song ever

LOS ANGELES (Reuters) – The 1982 hit “The Message” by Grandmaster Flash and the Furious Five was named the greatest hip hop song of all time on Wednesday, in the first such list by Rolling Stone magazine to celebrate the young but influential music genre.

“The Message,” which tops a list of 50 influential hip hop songs, was the first track “to tell, with hip hop‘s rhythmic and vocal force, the truth about modern inner-city life in America,” Rolling Stone said.

Grandmaster Flash and the Furious Five, a hip hop collective from the south Bronx in New York, was formed in 1978 and became one of the pioneers of the hip hop genre.

The full list spanned songs ranging from Sugarhill Gang’s 1979 hit “Rapper’s Delight,” which came in at No. 2, to Kanye West‘s 2004 hit “Jesus Walks,” which landed at No. 32.

“It’s a list that would have been a lot harder to do ten or 15 years ago because hip hop is so young,” Nathan Brackett, deputy managing editor of Rolling Stone, told Reuters.

“We’ve reached the point now where hip hop acts are getting into the (Rock and Roll) Hall Of Fame… it just felt like the right time to give this the real Rolling Stone treatment.”

Rolling Stone‘s top 10 featured mostly hip hop veterans, such as Run-D.M.C.’s 1983 track “Sucker M.C.’s,” Dr. Dre and Snoop Dogg’s 1992 hit “Nuthin’ But A ‘G’ Thang,” Public Enemy’s 1990 song “Fight The Power” and Notorious B.I.G’s 1994 hit “Juicy.”

Other influential artists in the top 50 songs included Beastie Boys, who came in at No. 19 with “Paul Revere,” and recordings by Jay-Z, Eminem, Missy Elliot, Outkast, Lauryn Hill, LL Cool J, Nas and the late rapper 2Pac.

The list of 50 songs was compiled by a 33-panel of members comprising Rolling Stone editors and hip hop experts. They included musician Ahmir “Questlove” Thompson of The Roots, who Brackett described as “an incredible encyclopedia” of both old and new hip hop knowledge.

Brackett noted that some songs considered to be one-hit wonders, such as Audio Two’s 1988 hit “Top Billin’,” made the final selection.

“The references in those songs become the building blocks of all these other songs down the road … they become touchstones, really part of the meat of hip hop songs going forward,” Brackett said.

The full list will be released online at RollingStone.com and in the pop culture magazine on newsstands on December7. The issue will feature four different covers of Eminem, Jay-Z, Notorious B.I.G. and 2Pac.

(Reporting By Piya Sinha-Roy, editing by Jill Serjeant)

Music News Headlines – Yahoo! News

Read More..

Lundbeck anticipates new drug “feast”

LONDON (Reuters) – Danish group Lundbeck is looking forward to a “feast” of new drugs to refresh its product line-up, kicking off next week with a possible European Union green light for a novel medicine to treat alcohol abuse.

In all, there is scope for regulatory approval of three medicines in 2013 – an impressive tally for a small company focused on brain disorders – as well as a potential partnership deal for a drug to fight the symptoms of Alzheimer’s disease.

“Sometimes people say it is feast or famine for this industry and we are in a feast phase, especially considering our size,” chief executive Ulf Wiinberg told Reuters.

Lundbeck needs these new drugs to replace lost sales from antidepressant Cipralex, sold as Lexapro in the United States, which is now coming off patent.

Doubts about the company’s ability to make the transition from reliance on Cipralex has taken its toll on the stock in recent months, with the shares underperforming the European drugs sector by 23 percent this year.

There have even been suggestions the Lundbeck Foundation, which owns a 70 percent stake, might delist the drugmaker.

Wiinberg said this option had not be discussed. “If we were working on it I would say something, but I have nothing to say.”

While Wiinberg has already said earnings will stall until 2015 as a result of patent losses, he is increasingly confident the pieces are in place to lift sales in the medium term.

The next catalyst could come as early as December 13 or 14, when Lundbeck expects the European Medicines Agency to decide whether or not to recommend Selincro for alcohol dependence. A positive decision would lead to approval early next year.

The drug is breaking new ground in an uncertain market, and Wiinberg said it was “a bit of a joker in our portfolio”. Analysts currently pencil in only modest sales.

More important will be the verdict from regulators in North America and Europe later next year on a new antidepressant being developed with Japanese partner Takeda Pharmaceutical that analysts see as a potential $ 1-$ 2 billion-a-year seller.

Developing new treatments for depression has proved an uphill battle for drugmakers in recent times but vortioxetine has produced encouraging clinical trial results and its unique mode of action and flexible dosing could make it a winner.

The third approval prospect for next year is Abilify Maintena, a once-monthly version of schizophrenia drug Abilify that Lundbeck is working on with Otsuka.

Further out, Lundbeck is developing a drug for the symptoms of Alzheimer’s – a more modest ambition than that of disease-modifying treatments which have so far failed to gain much traction in tackling the underlying causes of the disorder.

That drug will be ready to go into final-stage clinical testing next year and Wiinberg said he would look to strike a partnership deal for the product, known as LuAE58054, at the same time as preparing for Phase III trials.

(Editing by Dan Lalor)

Medications/Drugs News Headlines – Yahoo! News

Read More..

Dems call Republicans 'hostage takers' on debt talks

Screen shot from GOPHostageTakers.com

House Democrats on Wednesday launched a new microsite, GOPHostageTakers.com, criticizing Republican leaders for not holding a vote to exclusively extend middle-income tax rates for another year as part of avoiding the so-called fiscal cliff.

Current tax rates for all income levels are set to automatically increase in 2013 unless Congress takes action this year. Most Republicans want to extend the current rates for all income levels, while Democrats want taxes to increase for households earning more than $250,000 annually.

The Democratic Congressional Campaign Committee launched the site as part of a larger messaging effort to goad Republicans into voting on a bill that excludes those earning more than $250,000 from the rate extension.

This week, House Minority Leader Nancy Pelosi, a California Democrat, submitted a "discharge petition" that would force a vote on a bill to extend rates only for middle-class taxpayers, but only if she can persuade 218 members of the Republican-led House to sign it. (Realistically, it's unlikely.) On the microsite, House Democrats list the names of some Republicans they consider "vulnerable" who have declined to sign Pelosi's petition.

Earlier this year, the Republican-led House approved a bill to extend tax rates for all income brackets while the Democrat-controlled Senate passed a measure that extends them for households under the $250,000 level.

Read More..

Dems call Republicans 'hostage takers' on debt talks

Screen shot from GOPHostageTakers.com

House Democrats on Wednesday launched a new microsite, GOPHostageTakers.com, criticizing Republican leaders for not holding a vote to exclusively extend middle-income tax rates for another year as part of avoiding the so-called fiscal cliff.

Current tax rates for all income levels are set to automatically increase in 2013 unless Congress takes action this year. Most Republicans want to extend the current rates for all income levels, while Democrats want taxes to increase for households earning more than $250,000 annually.

The Democratic Congressional Campaign Committee launched the site as part of a larger messaging effort to goad Republicans into voting on a bill that excludes those earning more than $250,000 from the rate extension.

This week, House Minority Leader Nancy Pelosi, a California Democrat, submitted a "discharge petition" that would force a vote on a bill to extend rates only for middle-class taxpayers, but only if she can persuade 218 members of the Republican-led House to sign it. (Realistically, it's unlikely.) On the microsite, House Democrats list the names of some Republicans they consider "vulnerable" who have declined to sign Pelosi's petition.

Earlier this year, the Republican-led House approved a bill to extend tax rates for all income brackets while the Democrat-controlled Senate passed a measure that extends them for households under the $250,000 level.

Read More..

PlayStation 3 was the world’s No.1 Netflix streaming device this year

There are dozens of devices that can stream Netflix (NFLX), but only one can machine be crowned the king of the living room. According to Netflix, that device is Sony’s (SNE) PlayStation 3 console. Without revealing any specific figures, Netflix announced on its blog “in the U.S. and globally, PS3 is the largest TV-connected platform in terms of Netflix viewing” and that “at times, PS3 even surpassed the PC in hours of Netflix enjoyment to become our No. 1 platform overall.” 

Netflix’s blog is quick to mention why the PS3 is the most popular streaming device this year, applauding it for being the first console to have 1080p HD video and 5.1-channel Dolby Digital Plus surround sound, post-play, second screen controls, subtitles and easy app updates.

While the Xbox 360 is gaining ground in terms of how many hours users spend watching videos on it, streaming video services such as Netflix requires an Xbox LIVE Gold subscription. One reason why the PlayStation 3 might be leading Netflix streaming is because it doesn’t require a subscription fee to have access to the Netflix app, or any other streaming video app such as Amazon (AMZN) Instant Video.

“The PlayStation and Netflix communities both share a strong passion for high quality entertainment,” Sony Computer Entertainment of America CEO and president Jack Tretton said. “Netflix provides a fantastic experience for watching TV shows and movies on PS3, and our joint development will continue to produce innovations for our customers that further demonstrate PS3 as the true home for entertainment in the living room.”

Get more from BGR.com: Follow us on Twitter, Facebook

Gaming News Headlines – Yahoo! News

Read More..

Lundbeck anticipates new drug “feast”

LONDON (Reuters) – Danish group Lundbeck is looking forward to a “feast” of new drugs to refresh its product line-up, kicking off next week with a possible European Union green light for a novel medicine to treat alcohol abuse.

In all, there is scope for regulatory approval of three medicines in 2013 – an impressive tally for a small company focused on brain disorders – as well as a potential partnership deal for a drug to fight the symptoms of Alzheimer’s disease.

“Sometimes people say it is feast or famine for this industry and we are in a feast phase, especially considering our size,” chief executive Ulf Wiinberg told Reuters.

Lundbeck needs these new drugs to replace lost sales from antidepressant Cipralex, sold as Lexapro in the United States, which is now coming off patent.

Doubts about the company’s ability to make the transition from reliance on Cipralex has taken its toll on the stock in recent months, with the shares underperforming the European drugs sector by 23 percent this year.

There have even been suggestions the Lundbeck Foundation, which owns a 70 percent stake, might delist the drugmaker.

Wiinberg said this option had not be discussed. “If we were working on it I would say something, but I have nothing to say.”

While Wiinberg has already said earnings will stall until 2015 as a result of patent losses, he is increasingly confident the pieces are in place to lift sales in the medium term.

The next catalyst could come as early as December 13 or 14, when Lundbeck expects the European Medicines Agency to decide whether or not to recommend Selincro for alcohol dependence. A positive decision would lead to approval early next year.

The drug is breaking new ground in an uncertain market, and Wiinberg said it was “a bit of a joker in our portfolio”. Analysts currently pencil in only modest sales.

More important will be the verdict from regulators in North America and Europe later next year on a new antidepressant being developed with Japanese partner Takeda Pharmaceutical that analysts see as a potential $ 1-$ 2 billion-a-year seller.

Developing new treatments for depression has proved an uphill battle for drugmakers in recent times but vortioxetine has produced encouraging clinical trial results and its unique mode of action and flexible dosing could make it a winner.

The third approval prospect for next year is Abilify Maintena, a once-monthly version of schizophrenia drug Abilify that Lundbeck is working on with Otsuka.

Further out, Lundbeck is developing a drug for the symptoms of Alzheimer’s – a more modest ambition than that of disease-modifying treatments which have so far failed to gain much traction in tackling the underlying causes of the disorder.

That drug will be ready to go into final-stage clinical testing next year and Wiinberg said he would look to strike a partnership deal for the product, known as LuAE58054, at the same time as preparing for Phase III trials.

(Editing by Dan Lalor)

Medications/Drugs News Headlines – Yahoo! News

Read More..